{"ticker": {"uuid": "8d51c352-69e9-44dc-a61a-5ab77ff8c491", "symbol": "002773", "name": "Chengdu Kanghong Pharmaceutical Group Co., Ltd", "exchange": "SHZ", "country": "CN", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "ETFs Investing in Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE1tN2xmQWVGNEZfU3hyQVJHc3ZQT1JseDktWHY5LXJJYmFrVUctVUFUYjdlVzVUZGhlVjViM0xudmFTRlZYRE5CWGNjVjdfZFpZWmNvQlRhcVVHYndqb3N6ZVE5WQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T07:51:32+00:00", "published_display": "17 Jul 2026 07:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPMWFEWUdoMUxmSkc2V0pOZkktbWY0bGZLWVhnZHZMMnF3RFhIazhINi04TWNXVlJhTk1pRHA5OXFZMGo1QlJ1M051SkhDOGl6M3FuX2xEOVdnUHRxQ0VXd1NGWFJkRjVnMXplWjNyOTl5Q3pmNEh2LU54d052UmxQNldSdDMzMmUyTDlSZi1CUzFPb2JDUW1EdnNWanNub0RoaVhyeFZ0Z1ZuSkoxeFRtdmxFR2NCR3k2UnZBX3J2UDRneURqYk8yVkpQNEcyR3J5LVJwb0lQR3RkWDBLNnFNNl9FMTdMZw?oc=5", "source_name": "PR Newswire", "published_at": "2021-02-03T08:00:00+00:00", "published_display": "03 Feb 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chengdu Kanghong Pharma buys Israel's IOPtima for $56m - Globes", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMXB2S1RzUUNDZ3NEUFVkYjE4a0R6VzRod1lzQWdNQUNUOG12aF90LTV1dG45aGdVaEFWcXEySFo5dlluOEVuUlZmcDMtc3RjTnN6S1BzQ2Rrc1FfSmVPUjNTVFFOLURlZ3FaUXBrWUJ3N1M2em54dWF5c2x1eEFXNHRFREUzYW9CVWFpU1pTOXhlNUk2?oc=5", "source_name": "Israel Business News", "published_at": "2017-11-21T08:00:00+00:00", "published_display": "21 Nov 2017 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ETFs Investing in Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE1tN2xmQWVGNEZfU3hyQVJHc3ZQT1JseDktWHY5LXJJYmFrVUctVUFUYjdlVzVUZGhlVjViM0xudmFTRlZYRE5CWGNjVjdfZFpZWmNvQlRhcVVHYndqb3N6ZVE5WQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T07:51:32+00:00", "published_display": "17 Jul 2026 07:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPMWFEWUdoMUxmSkc2V0pOZkktbWY0bGZLWVhnZHZMMnF3RFhIazhINi04TWNXVlJhTk1pRHA5OXFZMGo1QlJ1M051SkhDOGl6M3FuX2xEOVdnUHRxQ0VXd1NGWFJkRjVnMXplWjNyOTl5Q3pmNEh2LU54d052UmxQNldSdDMzMmUyTDlSZi1CUzFPb2JDUW1EdnNWanNub0RoaVhyeFZ0Z1ZuSkoxeFRtdmxFR2NCR3k2UnZBX3J2UDRneURqYk8yVkpQNEcyR3J5LVJwb0lQR3RkWDBLNnFNNl9FMTdMZw?oc=5", "source_name": "PR Newswire", "published_at": "2021-02-03T08:00:00+00:00", "published_display": "03 Feb 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chengdu Kanghong Pharma buys Israel's IOPtima for $56m - Globes", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMXB2S1RzUUNDZ3NEUFVkYjE4a0R6VzRod1lzQWdNQUNUOG12aF90LTV1dG45aGdVaEFWcXEySFo5dlluOEVuUlZmcDMtc3RjTnN6S1BzQ2Rrc1FfSmVPUjNTVFFOLURlZ3FaUXBrWUJ3N1M2em54dWF5c2x1eEFXNHRFREUzYW9CVWFpU1pTOXhlNUk2?oc=5", "source_name": "Israel Business News", "published_at": "2017-11-21T08:00:00+00:00", "published_display": "21 Nov 2017 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 42, "total_relevant": 3, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 3, "score": 50, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 22.04, "latest_week": "2026-07-17", "one_week_move": -1.2, "four_week_move": 11.3, "twelve_week_move": -10.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.146812, "market_dynamics_buy_signal": false, "relative_strength": -29.436916, "fair_value_gap": -5.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 42.8176, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.2% over one week, +11.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 1}, {"label": "PR Newswire", "count": 1}, {"label": "Israel Business News", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.2% over one week, +11.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ETFs Investing in Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A Stocks"}], "updated_at": "2026-07-22T12:13:46.619512+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}